Evidence map›Paper›PMID 22393533›Full record

ReviewCold Spring Harbor perspectives in medicine2012

Tumor endothelial cells.

Andrew C Dudley

Open access · bronzeAbstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 238 papers.

0numbers the graph read from it
0cells of the map it votes in
238citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

238 citing papers in PubMed, 394 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Polymeric Nanocarriers with pH-Dependent Release for Tumor-Specific Delivery.Recent advances in drug delivery and formulation · 2026
    Review
  17. PSMA expression in hepatic colorectal cancer metastasis.Journal of pathology and translational medicine · 2026
    Article
  18. Review
  19. Article
  20. Imipenem/Cilastatin in Embolization: From Antibiotic to Therapeutic Agent.Cardiovascular and interventional radiology · 2025
    Review

178 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Andrew C DudleyDepartment of Cellular and Molecular Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599, USA; and McAllister Heart Institute, Chapel Hill, North Carolina 27599, USA. acdudley@med.unc.edu
University of North Carolina at Chapel Hill · US

Funding

Targeting the vasculature to enhance anti-tumor immunityR01CA177875 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Andrew Carl Dudley · 2014 to 2026
$4.5M
Tumor endothelial cell abnormalitiesR00CA140708 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUDLEY, ANDREW CARL · 2011 to 2013
$732k
Characterizing tumor endothelial cell abnormalities to develop rational anti-angiK99CA140708 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUDLEY, ANDREW CARL · 2009 to 2010
$264k
NCI NIH HHS CA140708NCI NIH HHS K99 CA140708NCI NIH HHS R00 CA140708NCI NIH HHS R01 CA177875
6 · The paper itself

Abstract

The vascular endothelium is a dynamic cellular "organ" that controls passage of nutrients into tissues, maintains the flow of blood, and regulates the trafficking of leukocytes. In tumors, factors such as hypoxia and chronic growth factor stimulation result in endothelial dysfunction. For example, tumor blood vessels have irregular diameters; they are fragile, leaky, and blood flow is abnormal. There is now good evidence that these abnormalities in the tumor endothelium contribute to tumor growth and metastasis. Thus, determining the biological basis underlying these abnormalities is critical for understanding the pathophysiology of tumor progression and facilitating the design and delivery of effective antiangiogenic therapies.

Indexed as

Angiogenesis InhibitorsAnimalsBlood VesselsDisease ProgressionEndothelial CellsEndothelium, VascularHumansMyocytes, Smooth MuscleNeoplasm MetastasisNeoplasmsNeovascularization, PhysiologicTumor Cells, CulturedTumor MicroenvironmentVascular Endothelial Growth Factor AVenulesAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Identifiers

PMID22393533
PMCPMC3282494
OpenAlexW2102297721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.